Cardiac rehabilitation (CR) has evolved from foundations as a postmyocardial infarction mobilization strategy for patients who were typically unstable, into a comprehensive, multidisciplinary program ...
The dupilumab group had significant differences vs the other groups, with increased values for FEF 25-75% at months 6 and 12, and for FEF 75% at month 12. Four biologics — omalizumab, mepolizumab, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback